Evidence map›Paper›PMID 26905304›Full record

ArticleUrologic oncology2016

The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men.

Michael Kongnyuy, Abhinav Sidana, Arvin K George, Akhil Muthigi, Amogh Iyer, Michele Fascelli, Meet Kadakia, Thomas P Frye, Richard Ho, Francesca Mertan and 7 more

Open access · greenAbstract read
In one paragraph

Article in Urologic oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Reply by the Authors.Urology · 2017
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Michael KongnyuyUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Abhinav SidanaUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Arvin K GeorgeUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Akhil MuthigiUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Amogh IyerUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Michele FascelliUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Meet KadakiaUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Thomas P FryeUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Richard HoUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Francesca MertanMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.
M Minhaj SiddiquiDepartment of Urology, University of Maryland Medical School, Baltimore, MD.
Daniel SuUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Maria J MerinoLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Baris TurkbeyMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Peter L ChoykeMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Bradford J WoodCenter for Interventional Oncology, National Cancer Institute & NIH Clinical Center, National Institutes of Health, Bethesda, MD.
Peter A PintoUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: pintop@mail.nih.gov.
National Institutes of Health · USNational Cancer Institute · USUniversity of Maryland, Baltimore · US

Funding

Center for Interventional OncologyZIDBC011242 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WOOD, BRADFORD J · 2009 to 2025
$18.7M
Prostate SectionZIABC011081 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PINTO, PETER · 2009 to 2025
$15.2M
Interventional OncologyZIACL040015 · CLC · CLINICAL CENTER · PI WOOD, BRADFORD · 2009 to 2025
$0k
Intramural NIH HHS ZIA BC011081
6 · The paper itself

Abstract

introductionAfrican-American (AA) men tend to harbor high-risk prostate cancer (PCa) and exhibit worse outcomes when compared to other groups. It has been postulated that AA men may harbor more anterior prostate lesions (APLs) that are undersampled by the standard transrectal ultrasound guided-biopsy (SBx), potentially resulting in greater degree of Gleason score (GS) upgrading at radical prostatectomy. We aimed to evaluate the detection rate of anterior PCa significance of APLs in AA men on multiparametric magnetic resonance imaging (mpMRI) and compare it to a matched cohort of White/Other (W/O) men. MATERIALS AND

methodsA review of 1,267 men who had an mpMRI with suspicious prostate lesions and who underwent magnetic resonance transrectal ultrasound fusion-guided biopsy (FBx) with concurrent SBx in the same biopsy session was performed. All AA men were matched to a control group of W/O using a 1:1 propensity score-matching algorithm with age, prostate-specific antigen, and prostate volume as matching variables. Logistic regression analysis was used to determine predictors of APLs in AA men.

resultsOf the 195 AA men who underwent mpMRI, 93 (47.7%) men had a total of 109 APLs. Prior negative SBx was associated with the presence of APLs in AA men (Odds ratio = 1.81; 95% CI: 1.03-3.20; P = 0.04). On multivariate logistic regression analysis, smaller prostate (P = 0.001) and rising prostate-specific antigen (P = 0.007) were independent predictors of cancer-positive APLs in AA men. Comparative analysis of AA (93/195, 47.7%) vs. W/O (100/194, 52%) showed no difference in the rates of APLs (P = 0.44) or in cancer detection rate within those lesions or the distribution of GS within those cancers (P = 0.63) despite an overall higher cancer detection rate in AA men (AA: 124/195 [63.6%] vs. W/O: 97/194 [50.0%], P = 0.007). In cases where APLs were positive for PCa on FBx, the GS of APL was equal to the highest GS of the entire gland in 82.9% (29/35) and 90.9% (30/33) of the time in AA and W/O men, respectively.

conclusionCancer-positive APLs represented the highest risk GS in most cases. AA men with prior negative SBx are twice as likely to harbor a concerning APL. In our cohort, AA and W/O men had comparable rates of APLs on mpMRI. Thus, differences in APLs do not explain the higher risk of AA men for deahth due to PCa. However, targeting of APLs via FBx can clinically improve PCa risk stratification and guide appropriate treatment options.

Indexed as

Magnetic Resonance ImagingAgedBlack or African AmericanHumansImage-Guided BiopsyMaleMiddle AgedNeoplasm GradingProstate-Specific AntigenProstatic NeoplasmsUnited StatesProstate-Specific AntigenAfrican-AmericanAnterior prostate lesionMultiparametric MRI

Identifiers

PMID26905304
PMCPMC7511973
OpenAlexW2284983568

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.